KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Ratio (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Equity Ratio for 11 consecutive years, with 0.85 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 1.55% to 0.85 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.85 through Dec 2025, down 1.55% year-over-year, with the annual reading at 0.85 for FY2025, 1.55% down from the prior year.
  • Equity Ratio hit 0.85 in Q4 2025 for CRISPR Therapeutics AG, down from 0.85 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.92 in Q1 2021 to a low of 0.83 in Q1 2023.
  • Historically, Equity Ratio has averaged 0.85 across 5 years, with a median of 0.85 in 2022.
  • Biggest five-year swings in Equity Ratio: rose 4.83% in 2021 and later decreased 6.77% in 2022.
  • Year by year, Equity Ratio stood at 0.87 in 2021, then fell by 4.11% to 0.84 in 2022, then increased by 1.0% to 0.84 in 2023, then increased by 2.05% to 0.86 in 2024, then fell by 1.55% to 0.85 in 2025.
  • Business Quant data shows Equity Ratio for CRSP at 0.85 in Q4 2025, 0.85 in Q3 2025, and 0.84 in Q2 2025.